Search
MVA-SARS-2-S
go.drugbank.com/drugs/DB16432InvestigationalMVA is a highly attenuated poxvirus vector[A226603] that has a high-level of biological safety due to its quality of being a non-replicating virus in mammalian hosts[L30458] and is used to develop vaccines … MVA-SARS-2-S is a COVID-19 vaccine candidate that contains a Modified Vaccinia Virus Ankara (MVA) vector expressing the SARS-CoV-2 spike protein[L30453].
AG0302-COVID19
go.drugbank.com/drugs/DB16435InvestigationalSponsored by Anges, Inc. in Japan, the AG0302-COVID19 is a DNA-based vaccine that recently completed Phase I/II trials (NCT04527081)[A226813, L30548].
V591
go.drugbank.com/drugs/DB16438InvestigationalThe V591 vaccine, part of Merck’s COVID-19 vaccine programming, was developed using a modified measles vaccine virus as a vector for COVID-19 antigen delivery[L30593].
Vafidemstat
go.drugbank.com/drugs/DB16446InvestigationalVafidemstat is under investigation in clinical trial NCT03867253 (Testing the Safety and Preliminary Efficacy of the New Drug ORY-2001 in Mild to Moderate Alzheimer's Disease).
Efzofitimod
go.drugbank.com/drugs/DB16453InvestigationalEfzofitimod (ATYR1923) is a fusion protein comprised of the immuno-modulatory domain of histidyl tRNA synthetase fused to the FC region of a human antibody. … It is a selective modulator of neuropilin-2 that downregulates the innate and adaptive immune response in inflammatory disease states.
XPro1595
go.drugbank.com/drugs/DB16454InvestigationalXPro1595 is an investigational dominant-negative protein that neutralizes soluble TNF.
Synonyms: -METHOXYPOLY(OXYETHANE-1,2-DIYL))PROPYL)CARBAMOYL)ETHYL)-2,5-DIOXOPYRROLIDIN-3-YL)-L-CYSTEINYL, HOMOSAPIENS TUMOR NECROSIS FACTOR,SOLUBLE FORM (V1>M, R31>C, C69>V, Y87>H, C101>A, A145>R), MONOMER, PEGYLATED ON CYSTEINE 31 : S-((3RS)-(2-((3-(.OMEGA.Human Interleukin 8
go.drugbank.com/drugs/DB16456InvestigationalInterleukin-8 is under investigation in clinical trial NCT05148234 (BMS-986253 in Myelodysplastic Syndromes).
TD-0903
go.drugbank.com/drugs/DB16463InvestigationalTD-0903 was investigated in clinical trials for its potential to treat acute lung injury (ALI) associated with COVID-19, including NCT04350736, NCT05091723 (a pharmacokinetics study in healthy participants